A New Genetic Clue to Friedreich Ataxia
Genetic diseases do not always occur equally across populations.
Some inherited disorders are concentrated in particular regions or ancestry groups because of the history and distribution of specific genetic variants.
Friedreich ataxia is one such disorder. It is most commonly found among people with European, Middle Eastern, South Asian and North African ancestry, while it has not been documented or is extremely rare in several other populations.
New research into the genetic history of the disorder may now help explain why.
What Is Friedreich Ataxia?
Friedreich ataxia is an autosomal recessive genetic disorder that progressively affects the nervous system.
People with the condition typically develop problems with balance and coordination, followed by difficulties with movement and speech. Muscle weakness and reduced sensation in the limbs can also occur.
The disorder can affect other organs as well. Hypertrophic cardiomyopathy, diabetes and skeletal abnormalities are among the complications associated with Friedreich ataxia.
The Role of the FXN Gene
The disease is primarily caused by an abnormal expansion of a GAA trinucleotide repeat in the FXN gene.
In healthy individuals, the GAA sequence occurs only a limited number of times. In people with Friedreich ataxia, the repeat can expand dramatically, sometimes reaching hundreds or more than a thousand repeats.
This expansion interferes with the normal functioning of the FXN gene and reduces production of the protein frataxin.
Why Frataxin Matters
Frataxin is a mitochondrial protein that plays an important role in cellular energy metabolism.
Mitochondria are responsible for producing much of the energy required by cells. Frataxin deficiency disrupts processes involving iron-sulfur clusters and mitochondrial energy production.
The resulting mitochondrial dysfunction and oxidative stress can particularly damage cells with high energy demands, including neurons and heart muscle cells.
Why Is the Disorder Concentrated in Certain Populations?
For years, researchers have known that Friedreich ataxia has an unusual geographical distribution.
It is relatively common in populations of European ancestry and is also found in parts of the Middle East, North Africa and the Indian subcontinent.
By contrast, the disorder has not been documented in several Southeast Asian, sub-Saharan African and Native American populations.
This uneven distribution has raised questions about the evolutionary history of the mutation responsible for the disease.
The Protomutation Discovery
A recent study identified a previously unrecognised type of genetic change described as a protomutation.
Rather than being the final mutation that directly produces Friedreich ataxia, the protomutation appears to represent an earlier genetic state that could eventually give rise to the pathogenic GAA repeat expansion.
The researchers found this genetic feature exclusively among people of Eurasian descent, providing a possible explanation for why the disorder is concentrated in those populations.
A Stepwise Evolutionary Process
The finding suggests that the disease-causing mutation may have developed through several genetic stages.
Instead of a fully expanded pathogenic repeat appearing suddenly, an initial genetic change may have created a more unstable DNA sequence.
Over generations, that sequence could have undergone further changes and eventually expanded into the mutation associated with Friedreich ataxia.
This provides a possible evolutionary explanation for the disorder's highly uneven global distribution.
Population History Could Hold the Answer
Genetic disorders can become concentrated in particular populations through processes such as the founder effect.
If a genetic variant develops in an ancestral population and is passed through subsequent generations, it can become more common among descendants of that population.
Researchers have previously suggested that founder effects and population history may contribute to the distribution of Friedreich ataxia.
Symptoms Usually Begin Early
Typical Friedreich ataxia often begins during childhood or adolescence.
Early signs can include difficulty walking, poor balance and problems coordinating movements.
As the disorder progresses, patients may experience speech difficulties, weakness, sensory problems and other neurological complications.
Heart disease and diabetes can also develop in affected individuals.
The Severity Can Vary
The size of the GAA repeat expansion is associated with the age at which symptoms begin and the severity of the disease.
Larger expansions are generally associated with earlier onset, while smaller expansions can result in later-onset forms.
This helps explain why the condition can vary significantly from one patient to another.
Why the New Finding Matters
Understanding how a disease-causing mutation originated can have implications beyond population genetics.
Tracing the sequence of genetic changes may help researchers better identify people at risk and improve understanding of how the mutation behaves.
It could also provide new clues for developing diagnostic strategies and treatments aimed at the underlying genetic mechanism.
Implications for Treatment Research
There is currently no complete cure for Friedreich ataxia. Medical care focuses on managing symptoms, preserving function and monitoring complications involving the heart, nervous system and metabolism.
However, researchers are exploring approaches designed to increase frataxin levels, address mitochondrial dysfunction and target other mechanisms involved in the disease.
Future Research
Potential treatment strategies under investigation include approaches aimed at increasing frataxin production, gene and protein-based therapies, antioxidants and other methods designed to reduce cellular damage.
A clearer understanding of how the disease-causing mutation developed could help researchers refine these approaches in the future.
Conclusion
The new genetic findings provide an important clue to one of the longstanding mysteries surrounding Friedreich ataxia: why is the disease concentrated in people of Eurasian ancestry?
The identification of a possible FXN protomutation that predates the pathogenic GAA expansion suggests that the disorder may have emerged through a stepwise genetic process in an ancestral Eurasian population.
The discovery not only sheds light on the evolutionary history of a rare neurological disease but could also provide useful insights for future research into genetic testing, disease mechanisms and potential treatments.
